All posts from in,

Breaking Down Biotech ETFs With Leverage

Looking for more expert commentary and daily trading ideas? The Benzinga Pro news and data platform has everything you need. Get exclusive, member-only access today with this deal.

SPDR S&P Biotech ETF ETF:XBI, LABD - Breaking Down Biotech ETFs With Leverage

Amid political grandstanding and valuation concerns, among other factors, the once high-flying healthcare sector has swiftly reversed course for the worse in recent weeks. The pain has been especially acute for biotechnology equities and exchange-traded funds.

Over the past month, four of the worst performing non-leveraged ETFs, including the worst overall, are healthcare funds. Three of those four are biotech ETFs.

However, some bearish leveraged biotech ETFs, namely the Direxion Daily S&P Biotech Bear 3X Shares LABD 8.43%, have emerged from the bearish cloud that has been cast over the biotech space.

“Since peaking on July 20, the S&P 500 Biotech Index has fallen 23 percent, double the broader S&P 500 Index during same period. It all started to unravel when Turing Pharmaceuticals raised the price of a 30-year old drug used for HIV treatment, by 5,000 percent to $750 per pill. Shortly after the New York Times published a story on Turing and...